From Transcriptome to Therapy: The ncRNA Revolution in Neurodevelopmental Disorders
Open Access
- 23 December 2025
- journal article
- review article
- Published by MDPI AG in Brain Sciences
- Vol. 16 (1) , 17
Abstract
Neurodevelopmental disorders (NDDs) such as autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and intellectual disability (ID) arise from disruptions of molecular programmes that coordinate neurogenesis, synaptogenesis, and circuit maturation. While genomic studies have identified numerous susceptibility loci, genetic variation alone accounts for only part of disease heritability, underscoring the importance of post-transcriptional and epigenetic regulation. Among these regulatory layers, non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), PIWI-interacting RNAs (piRNAs), and transfer RNA-derived small RNAs (tsRNAs), have emerged as central modulators of neural differentiation, synaptic plasticity, and intercellular signalling. Recent multi-omics and single-cell studies reveal that ncRNAs fine-tune chromatin accessibility, transcriptional output, and translation through tightly integrated regulatory networks. miRNAs shape neurogenic transitions and circuit refinement; lncRNAs and circRNAs couple chromatin architecture to activity-dependent transcription; and tsRNAs and piRNAs extend this regulation by linking translational control to epigenetic memory and environmental responsiveness. Spatial transcriptomics further maps ncRNA expression to vulnerable neuronal and glial subtypes across cortical and subcortical regions. Clinically, circulating ncRNAs, especially those packaged in extracellular vesicles, exhibit stable, disease-associated signatures, supporting their potential as minimally invasive biomarkers for early diagnosis and patient stratification. Parallel advances in RNA interference, antisense oligonucleotides, CRISPR-based editing, and vesicle-mediated delivery highlight emerging therapeutic opportunities. These developments position ncRNAs as both mechanistic determinants and translational targets in NDDs, offering a unifying framework that links genome regulation, environmental cues, and neural plasticity, and paving the way for next-generation RNA-guided diagnostics and therapeutics.Keywords
All Related Versions
This publication has 86 references indexed in Scilit:
- Circ_0049472 downregulation relieves Amyloid-β-induced neuronal injury by modulating PDE4A expression via targeting miR-22-3p in Alzheimer’s diseaseMetabolic Brain Disease, 2025
- The miR-34a-5p Promotes Hippocampal Neuronal Ferroptosis in Epilepsy by Regulating SIRT1Neurochemical Research, 2025
- The MNK-SYNGAP1 axis in specific learning disorder: gene expression pattern and new perspectivesEuropean Journal of Pediatrics, 2025
- Diagnostic Value of Serum miR-499a-5p in Chinese Children with Autism Spectrum DisordersJournal of Molecular Neuroscience, 2025
- Identification of diagnostic and therapeutic biomarkers for attention‐deficit/hyperactivity disorderThe Kaohsiung Journal of Medical Sciences, 2025
- H19/miR‐484 axis serves as a candidate biomarker correlated with autism spectrum disorderInternational Journal of Developmental Neuroscience, 2025
- Assessment of Expression of lncRNAs in Autistic PatientsJournal of Molecular Neuroscience, 2024
- NEAT1 Promotes Valproic Acid-Induced Autism Spectrum Disorder by Recruiting YY1 to Regulate UBE3A TranscriptionMolecular Neurobiology, 2024
- Expression Patterns of miRNAs in Egyptian Children with ADHD: Clinical Study with Correlation AnalysisJournal of Molecular Neuroscience, 2024
- Association study of a single nucleotide polymorphism in brain cytoplasmic 200 long-noncoding RNA and psychiatric disordersMetabolic Brain Disease, 2020